A PYMNTS Company

US: Pharma merger breezes through review

By  |  December 13, 2013

Pharmaceutical company Shire announced that it has been given clearance for its acquisition of ViroPharma Incorporated, a deal previously announced.

Shire announced Friday the expiration of the Hart-Scott-Rodino Act’s merger waiting period, though reports say the deal must meet certain requirements to finalize.

Should the deal go through, however, Shire is set to make the acquisition for about $4.2 billion. The strategic buyout would allow the company to broaden its rare disease treatment portfolio.

Full Content: Zacks

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.